1. Study protocol of a prospective single-arm multicenter clinical study to assess the safety and performance of the aXess hemodialysis graft: The pivotal study.
- Author
-
De Vriese AS, D'Haeninck A, Mendes A, Ministro A, Krievins D, Kingsmore D, Mestres G, Villanueva G, Rodrigues H, Turek J, Zieliński M, De Letter J, Coelho A, Loureiro LA, Tozzi M, Menegolo M, Alija PF, Theodoridis PG, Gibbs P, Ebrahimi R, Nauwelaers S, Kakkos SK, Matoussevitch V, Moll F, and Gargiulo M
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Prospective Studies, Prosthesis-Related Infections microbiology, Prosthesis-Related Infections etiology, Risk Factors, Time Factors, Treatment Outcome, Non-Randomized Controlled Trials as Topic, Arteriovenous Shunt, Surgical adverse effects, Arteriovenous Shunt, Surgical instrumentation, Blood Vessel Prosthesis, Blood Vessel Prosthesis Implantation adverse effects, Blood Vessel Prosthesis Implantation instrumentation, Graft Occlusion, Vascular etiology, Graft Occlusion, Vascular physiopathology, Kidney Failure, Chronic therapy, Kidney Failure, Chronic diagnosis, Prosthesis Design, Renal Dialysis, Vascular Patency
- Abstract
Background: Arteriovenous grafts (AVGs) are used for patients deemed unsuitable for the creation of an autogenous arteriovenous fistula (AVF) or unable to await maturation of the AVF before starting hemodialysis. However, AVGs are prone to infection and thrombosis resulting in low long-term patency rates. The novel aXess Hemodialysis Graft consists of porous polymeric biomaterial allowing the infiltration by cells and the growth of neotissue, while the graft itself is gradually absorbed, ultimately resulting in a fully functional natural blood vessel. The Pivotal Study will examine the long-term effectiveness and safety of the aXess Hemodialysis Graft., Methods: The Pivotal Study is a prospective, single-arm, multicenter study that will be conducted in 110 subjects with end-stage renal disease who are not deemed suitable for the creation of an autogenous vascular access. The primary efficacy endpoint will be the primary patency rate at 6 months. The primary safety endpoint will be the freedom from device-related serious adverse events at 6 months. The secondary endpoints will include the procedural success rate, time to first cannulation, patency rates, the rate of access-related interventions to maintain patency, the freedom from device-related serious adverse events and the rate of access site infections. Patients will be followed for 60 months. An exploratory Health Economic and Outcomes Research sub-study will determine potential additional benefits of the aXess graft to patients, health care institutions, and reimbursement programs., Discussion: The Pivotal study will examine the long-term performance and safety of the aXess Hemodialysis Graft and compare the outcome measures with historical data obtained with other graft types and autogenous AVFs. Potential advantages may include superior long-term patency rates and lower infection rates versus currently available AVGs and a shorter time to first cannulation compared to an autologous AVF. As such, the aXess Hemodialysis Graft may fulfill an unmet clinical need in the field of hemodialysis access., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Frans Moll is a consultant to Xeltis B.V. All other authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF